More about hyperprolactinemia

Por Serri, Omar, Ezzat, Shereen
Publicado em 2004

Diagnosis and management of hyperprolactinemia

Por Serri, Omar, Chik, Constance L., Ur, Ehud, Ezzat, Shereen
Publicado em 2003

The Role of Diabetes in Acromegaly Associated Neoplasia

Por Cheng, Sonia, Gomez, Karen, Serri, Omar, Chik, Constance, Ezzat, Shereen
Publicado no PLoS One (2015)

Metabolic Glucose Status and Pituitary Pathology Portend Therapeutic Outcomes in Acromegaly

Por Cheng, Sonia, Al-Agha, Rany, Araujo, Paula B., Serri, Omar, L. Asa, Sylvia, Ezzat, Shereen
Publicado em 2013

Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multic...

Por Sheppard, Michael, Bronstein, Marcello D., Freda, Pamela, Serri, Omar, De Marinis, Laura, Naves, Luciana, Rozhinskaya, Liudmila, Hermosillo Reséndiz, Karina, Ruffin, Matthieu, Chen, YinMiao, Colao, Annamaria
Publicado no Pituitary (2014)

Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-b...

Por Sheppard, Michael, Bronstein, Marcello D., Freda, Pamela, Serri, Omar, De Marinis, Laura, Naves, Luciana, Rozhinskaya, Liudmila, Hermosillo Reséndiz, Karina, Ruffin, Matthieu, Chen, YinMiao, Colao, Annamaria
Publicado no Pituitary (2015)